S Chandrashekara1, Vineeta Shobha2, B G Dharmanand3, Ramesh Jois4, Sharath Kumar5, Kurugodu Mathada Mahendranath6, Vikram Haridas7, Shiva Prasad8, Yogesh Singh9, Manisha Ashwin Daware10, Anupama Swamy11, R Subramanian12, Srirama Attappa Somashekar13, Arun Madhanaghatta Shanthappa14, K R Anupama1. 1. ChanRe Rheumatology and Immunology Center, Bangalore, Karnataka, India. 2. St. John's Medical College Hospital, Bangalore, Karnataka, India. 3. Sakra Hospital, Bangalore, Karnataka, India. 4. Kanva Diagnostics Center, Bangalore, Karnataka, India. 5. Columbia Asia Hospital, Bangalore, Karnataka, India. 6. Samarpan Health Centre, Bangalore, Karnataka, India. 7. Arthritis Superspeciality Center, Hubli, Karnataka, India. 8. Vikram Hospital Pty. Ltd., Mysore, Karnataka, India. 9. Manipal Hospital, Mysore, Karnataka, India. 10. Narayana Health City, Mysore, Karnataka, India. 11. Anurag Clinic, Mysore, Karnataka, India. 12. JSS Medical College, Mysore, Karnataka, India. 13. Bangalore Rheumatology Center, Bangalore, India. 14. Arushi Rheumatology Center, Tumkur, India.
Abstract
AIM: To estimate the prevalence of extra-articular manifestations (EAM) in rheumatoid arthritis (RA) patients and the impact of demographic, clinical and treatment factors. METHOD: The study was carried out as a part of 'Karnataka Rheumatoid arthritis comorbidity (KRAC) study' conducted at 14 centers across Karnataka, India between September 2014 and July 2015. The data were collected by trained clinical research associates using a structured pro forma, under the supervision of the consulting rheumatologists. Based on the factors evaluated, the study participants were classified as follows: age, < 30 years, 30-39 years, 40-49 years, 50-59 years and ≥ 60 years; and duration of illness prior to visiting rheumatologist (DOIP), ≤ 6 months, > 6 months-2 years, 2-10 years and > 10 years. The Disease Activity Score of 28 joints-3 (erythrocyte sedimentation rate) score was calculated for each patient by three variable methods. RESULTS: The total number of patients considered for the study after exclusion was 1716. The subjects had a mean (SD) age of 48.1 (12.71) years, the male-to-female ratio was 1 : 5, and median (range) of duration of RA was 48 (0.5-484) months. The prevalence of EAM noted was around 13%. EAM were more likely during the first 2 years of the disease (odds ratio [OR]: 1.465; P = 0.047) and increased with longer DOIP. The incidence was less in patients with low disease activity (OR: 0.657) and worse with the presence of deformities (OR: 2.1). CONCLUSION: The study corroborates the current concept of effective disease control to reduce the incidence/likelihood of EAM in RA patients.
AIM: To estimate the prevalence of extra-articular manifestations (EAM) in rheumatoid arthritis (RA) patients and the impact of demographic, clinical and treatment factors. METHOD: The study was carried out as a part of 'Karnataka Rheumatoid arthritis comorbidity (KRAC) study' conducted at 14 centers across Karnataka, India between September 2014 and July 2015. The data were collected by trained clinical research associates using a structured pro forma, under the supervision of the consulting rheumatologists. Based on the factors evaluated, the study participants were classified as follows: age, < 30 years, 30-39 years, 40-49 years, 50-59 years and ≥ 60 years; and duration of illness prior to visiting rheumatologist (DOIP), ≤ 6 months, > 6 months-2 years, 2-10 years and > 10 years. The Disease Activity Score of 28 joints-3 (erythrocyte sedimentation rate) score was calculated for each patient by three variable methods. RESULTS: The total number of patients considered for the study after exclusion was 1716. The subjects had a mean (SD) age of 48.1 (12.71) years, the male-to-female ratio was 1 : 5, and median (range) of duration of RA was 48 (0.5-484) months. The prevalence of EAM noted was around 13%. EAM were more likely during the first 2 years of the disease (odds ratio [OR]: 1.465; P = 0.047) and increased with longer DOIP. The incidence was less in patients with low disease activity (OR: 0.657) and worse with the presence of deformities (OR: 2.1). CONCLUSION: The study corroborates the current concept of effective disease control to reduce the incidence/likelihood of EAM in RApatients.
Authors: Katja Heinimann; Johannes von Kempis; Rafael Sauter; Michael Schiff; Tuulikki Sokka-Isler; Hendrik Schulze-Koops; Rüdiger Müller Journal: J Clin Med Date: 2018-03-13 Impact factor: 4.241